Inivata is a Leader

in Liquid Biopsy
 
 
Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

Our US Medicare-reimbursed lead product InVisionFirst-Lung is already transforming the lives of advanced NSCLC patients

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

Our Technology

Contact Us

Latest News and Events

Inivata to Present New Clinical Data on the Utility of Liquid Biopsy and InVisionFirst®-Lung at World Conference on Lung Cancer 2019

Research Triangle Park, NC, USA and Cambridge, UK, August 29, 2019 — Inivata, a leader in liquid biopsy, is pleased to announce that ... Read More

Circulating tumor DNA assay and survival in patients with metastatic, non-small cell lung cancer

Jennifer L. Ersek, Madeline Hosking, James Symanowski, Qing Zhang, Emma Green, Edward S. Kim Read More

ESMO

ESMO

Event expiration date display - 27 SEPT - 1 OCT 2019

Location: Barcelona Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

We are pleased to sponsor the upcoming @HBAnet event - Reframing Healthcare with Dr. Zeev Neuwirth https://t.co/vmIwP9KEPt

The passion and dedication of the global #lungcancer community never ceases to amaze, and this year's #WCLC19 was no different. Thank you to all who joined us this year in #Barcelona. We hope to see you again next year for #WCLC20! #LCSM #Hope

First at the #precisionmedicine session is @HosseinBorghaei to discuss the pooled analysis of KN021G, KN189, and KN407 for pembro plus chemo for aNSCLC.